About Mekonos
Mekonos is a company based in Palo Alto (United States) founded in 2016 by Greg Sitters, Steven Banerjee, and Anil Narasimha. Mekonos has raised $29.6 million across 2 funding rounds from investors including Novartis, Debiopharm and Magnetar Capital. Mekonos operates in a competitive market with competitors including StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
- Headquarter Palo Alto, United States
- Founders Greg Sitters, Steven Banerjee, Anil Narasimha
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$29.6 M (USD)
in 2 rounds
-
Latest Funding Round
$25 M (USD), Series A
Nov 09, 2021
-
Investors
Novartis
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Mekonos
Unlock access to complete
Systems Team
1 people
Sr. Team
1 people
Co Team
1 people
Creative and Marketing Team
1 people
Senior Team
1 people
Unlock access to complete
Funding Insights of Mekonos
Mekonos has successfully raised a total of $29.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $25 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $25.0M
-
First Round
First Round
(23 Nov 2020)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Series A - Mekonos | Valuation | Magnetar , TDK Ventures | |
| Nov, 2020 | Amount | Series A - Mekonos | Valuation | Novartis |
Investors in Mekonos
Mekonos has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Debiopharm and Magnetar Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Magnetar Capital is engaged in alternative asset management.
|
Founded Year | Domain | Location | |
|
Early-stage tech startups are invested in globally by TDK Ventures.
|
Founded Year | Domain | Location | |
|
Investment firm focused on finance and technology opportunities.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mekonos
Financial Statements - Mekonos
Mekonos Comparisons
Competitors of Mekonos
Mekonos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Sixfold Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
AAV-based gene therapies for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| domain | founded_year | HQ Location |
Laboratory and computational services for DNA proximity analysis are provided.
|
|
| domain | founded_year | HQ Location |
Viral immunotherapies are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Oligonucleotide delivery systems are developed for targeted gene therapy.
|
|
| domain | founded_year | HQ Location |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
Frequently Asked Questions about Mekonos
Mekonos was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Mekonos is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Steven Banerjee is the current CEO of Mekonos. They have also founded this company.
Mekonos is a funded company, having raised a total of $29.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.6M, raised on Nov 23, 2020.
Mekonos was founded in 2016 and is based in Palo Alto, United States. Nanorobotic chips made from silicon are developed by the company for use in cell engineering. Biomolecules are delivered to cells via these chips to enable genetic modifications. The technology supports cell therapy processes, particularly for cancer treatment, within the biotechnology sector. Operations focus on advancing nanorobotics for therapeutic applications.
Mekonos's top competitors include Phase Genomics, Genedit and CellFE.
Mekonos has 14 investors. Key investors include Novartis, Debiopharm, Magnetar Capital, TDK Ventures, and Sands Capital.